Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Oral Bioavailability of Quizartinib in Healthy Subjects
NCT04796831Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Percentage of Absolute Oral Bioavailability for Quizartinib up to 504 hours. Started Apr 2021; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04796831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796831.